On September 5, 2023, the United States Government Accountability Office (GAO) published a report that bears particular significance for healthcare and pharmaceutical law professionals: Medicare Part D: CMS Should Monitor Effects of Rebates on Plan Formularies and Beneficiary Spending.
The report represents the GAO’s comprehensive assessment of Medicare Part D, with a focus on the role of rebate arrangements within pharmaceutical markets. These rebates, central in the relationship between manufacturers and payers, can have a profound impact on several areas, including drug spending, utilization, and industry competition.
Upon a completion of their detailed review, the GAO has issued a recommendation to the Centers for Medicare and Medicaid Services (CMS). The advisory body urges CMS to monitor the effects of rebates on plan formularies and on beneficiary spending. This advice highlights an important point for the legal professionals working closely with pharmaceutical corporations or law firms involved in healthcare litigation: the ongoing government attention towards Medicare Part D and its policies.
This report is a must-read for attorneys and in-house lawyers who are keen to keep updated with the regulatory emphasis on transparency in the pharmaceutical sector and the evolving legal landscape of healthcare in the United States.
While the full text of the report hasn’t been made available directly, the focus of its contents can be gleaned from the provided link. A close watch in this area is warranted, given the GAO’s shift towards data transparency and their inclination to push for policy changes that would directly affect healthcare services, beneficiaries, and the broader pharmaceutical industry.